CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma

CASI Pharmaceuticals, Inc.

, a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announced today that the China Food and Drug Administration (CFDA) has approved the Company's application to conduct a Phase 2 global clinical trial in ovarian clear cell carcinoma (OCCC) patients for its proprietary drug candidate ENMD-2076.  The approval will allow CASI to expand its ongoing Phase 2 OCCC trial currently underway in multiple centers in North America with Princess Margaret Cancer Centre in Toronto, Canada as the lead institution.  This will be the Company's third approval of a global Phase 2 clinical trial in China, the first being for advanced triple-negative breast cancer in which the first patient was enrolled last week at the Cancer Hospital of Chinese Academy of Medical Science in Beijing and the second being for advanced soft tissue sarcoma.  More information about the three trials can be found at www.clinicaltrials.gov. Ken K. Ren, Ph.D., CASI's Chief Executive Officer, commented, "Our excitement about this trial is two-fold. First, CFDA's approval of this third application supports